New hope for Tough-to-Treat colon cancer: phase 3 trial launches
NCT ID NCT07525206
First seen Apr 15, 2026 · Last updated May 04, 2026 · Updated 5 times
Summary
This study tests a new drug, telisotuzumab adizutecan, combined with bevacizumab, against the standard treatment (LONSURF plus bevacizumab) in adults with advanced colorectal cancer that no longer responds to other therapies. About 700 participants worldwide will be randomly assigned to one of the two treatment groups. The goal is to see if the new combination shrinks tumors or helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.